latency period of 2 to 8 weeks between drug exposure and symptoms, as well as a long disease course, with frequent flare-ups, despite drug discontinuation.DRESS is rare, with unknown incidence and prevalence, being associated with a mortality of 5-10% [1] , although some studies have shown lower death rates [2, 3] .
Multiple drug hypersensitivitysyndrome (MDHS)is characterized by sensitization to ≥2 chemically unrelated drugs [4] . DRESS is the SCAR most frequently associated with MDHS, which can complicate up to 18% of DRESS cases [5] . MDHS can be distinguished from DRESS flare-ups by the presence of sensitization to multiple drugs, proven by skin or in vitro tests [4] .
We describe the case of a 37-year-old female, admitted to Pulmonology Department for high fever, pulmonary infiltrates and left pleural effusion, described in CT scan as "loculated empyema with gas inside, suggesting dense exudate".Her previous history included tuberculosis (TB) at 12 years of age, uneventfully treated with isoniazide, rifampicin, pyrazinamide andethambutol (HRZE) and severe depression 5 months earlier, for which she was on olanzapine, sertraline and diazepam. Complicated community acquired pneumoniae was assumedand piperacillin/tazobactamand,a few days later, vancomycin,were started (figure 1), along with pleural drainage, hampered by loculation. Pleural fluid analysis showed bronchoalveolar lavage and gastric aspirate were negative for Acid-fast bacilli (AFB) and M. tuberculosis DNA. As clinical condition kept worsening, antibiotics were stoppedand HRZE wasstarted for suspected TB. Seven days later, Allergy and Dermatology specialists were called for a suspected SCAR.
The patient presented a maculopapular rash and facial edema that started on the first day of HRZE, eosinophilia of 1750cells/µL (baseline: 150) and acute kidney injury (creatinine >2mg/ml). Fever over 38ºC was present since admissionbutworsenedafterinitial improvement (figure 1). Skin biopsy was compatible with a hypersensitivity reaction; no viral reactivationswere observed (CMV, Parvovirus B19, EBV, Herpes simplex 1&2, herpes 6&7).A diagnosis of DRESS syndrome was made (RegiSCAR criteria=6) [3, 6] . HRZE was stopped and prednisolone 1mg/kg (60mg) was started [7] , with marked clinical and analytical improvement of DRESS signs and symptoms, allowing slow tapering of steroids over 8 weeks [7] . However, pleural fluid cultures eventually becamepositive for M. tuberculosis, confirmingTB.
Review of electronic records showed that the patientwas first treated with piperacillin/tazobactam for 14 days, plus vancomycin for 10 days, which were then switched to HRZE. Although the rash started on the same day as HRZE, eosinophil counts >700cells/µL were present before anti-TB drugs introduction. Although vancomycincannot be excludedas causative, the longer exposure time to piperacillin/tazobactammade it a more likely culprit.
Because the patient received HRZE for seven daysduring the most severe phase of DRESS syndrome, the possibility of sensitization to these drugs,in the setting ofMDHS,was considered [4] . The severity of initialrespiratory symptoms meant that TB needed to be J Investig Allergol Clin Immunol 2020; Vol. 30(1) ©2019 Esmon Publicidad doi: 10.18176/jiaci.0446 quickly addressed and allergy tests were deemed unfeasible, as the patient was still onprednisolone [8] . Therefore, HRZE reintroduction was decided to be trialed in an inpatient regime, one drug at a time, with a three days interval, starting with the most needed drugs. Six days after reintroduction of isoniazid (INH), and three days after ethambutol (EB), maculopapularrash relapsed, eosinophil counts doubled to 440cells/µL and treatment was withheld.
Patch tests to piperacillin/tazobactam, vancomycin, INH, EB, Rifampicin (RFP), Pyrazinamide (PZA)were performed according to previously published guidelines [8, 9] Although LTT was positive for all anti-TB drugs tested, reevaluation of its results (figure 2B, supplementary files)allowed the identification of higher SI to INH and RFP, as well as a doseresponse curve to these two drugs, which was not present for EB and PZA.In view of these results,an alternative schemewas devised, which included EB and PZA, levofloxacin and linezolid for 18 months. Ethionamide was considered but avoided based on possible crossreactivity with INH and a positive LTT (SI = 11.4plus presence of a dose-response curve).
Drugs were planned to be sequentially introduced following the ensuing "rules": 1) start with one drug at a time, 2) start with the drugs posing higher risk (EB and PZA), 3) allow a seven days interval between each new drug, to clearly establish tolerance, 4) start with full-doses of each drug to reduce the risk of TB resistance to treatment.
EB was startedat day 1, PZA at day 8, levofloxacin at day 22 and linezolid at day 34, with delays caused by complaints of isolated, episodic,skin pruritus. The patienthas been successfully treated with these drugs for the last 12months, without significative side effects.
In summary, we report a case of MDHS, confirmed by positive skin andinvitro tests [4] and positive rechallengeto INH, in the setting ofDRESS syndrome to piperacillin/tazobactam or vancomycin.Some unanswered questions hamper this work: have we sensitized the patient to INH during the first reintroduction attempt or was she already sensitized? Which arethe best criteria to value LTT results (SI alone vs SI plus dose response curves)?Despite the challenging combination of severeTB with DRESS and MDHS to the most important anti-TB drugs, the judicious use of a combination of allergy tests and the devoted involvement of a multidisciplinary team allowed this patient to successfully receive the most effective and less toxic treatment possible.
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